Fabio
76b8ec33a7
Ingested titles 12–51 and 54 from OLRC USLM XML @119-100 (the whole Code now, uniform edition; Title 53 is reserved/empty). LegalText 11,221 -> 59,740; repo total 105,704 records. Deterministic (byte-identical rerun, verified on Title 42's 8,356 sections); make check green. make legal-us-code default now covers every title. Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
54 lines
2.6 KiB
Markdown
54 lines
2.6 KiB
Markdown
---
|
||
type: "LegalText"
|
||
title: "21 U.S.C. § 399a"
|
||
description: "Office of the Chief Scientist"
|
||
jurisdiction: "us"
|
||
corpus: "united_states_code"
|
||
kind: "code_section"
|
||
title_number: 21
|
||
title_name: "FOOD AND DRUGS"
|
||
chapter_number: "9"
|
||
chapter_name: "FEDERAL FOOD, DRUG, AND COSMETIC ACT"
|
||
section: "399a"
|
||
citation: "21 U.S.C. § 399a"
|
||
status: "current"
|
||
release_point: "119-100"
|
||
release_date: "2026-06-26"
|
||
source: "official"
|
||
source_url: "https://uscode.house.gov/download/releasepoints/us/pl/119/100/xml_usc21@119-100.zip"
|
||
source_identifier: "/us/usc/t21/s399a"
|
||
source_file: "data/legal/raw/us/code/title-21/usc21.xml"
|
||
source_hash: "e5e51acdbee12cfe508bd79042a18425e0f3017d6c7675c854b466516d7b710f"
|
||
raw_snapshot_hash: "3dbd7a61c8616baefb8459bd8dac3b93242106deb416308c8d4dd5a9143176d1"
|
||
text_hash: "59218da3a6db851c1db473fd833c1316d2f9aa131ca47bb55ea93a8f0f760d2c"
|
||
retrieved_at: "2026-07-04"
|
||
confidence: "official"
|
||
tags: ["legal", "us-code"]
|
||
---
|
||
|
||
# 21 U.S.C. § 399a - Office of the Chief Scientist
|
||
|
||
## Text
|
||
|
||
(a) Establishment; appointment The Secretary shall establish within the Office of the Commissioner an office to be known as the Office of the Chief Scientist. The Secretary shall appoint a Chief Scientist to lead such Office.
|
||
|
||
(b) Duties of the Office The Office of the Chief Scientist shall—
|
||
|
||
(1) oversee, coordinate, and ensure quality and regulatory focus of the intramural research programs of the Food and Drug Administration;
|
||
|
||
(2) track and, to the extent necessary, coordinate intramural research awards made by each center of the Administration or science-based office within the Office of the Commissioner, and ensure that there is no duplication of research efforts supported by the Reagan-Udall Foundation for the Food and Drug Administration;
|
||
|
||
(3) develop and advocate for a budget to support intramural research;
|
||
|
||
(4) develop a peer review process by which intramural research can be evaluated;
|
||
|
||
(5) identify and solicit intramural research proposals from across the Food and Drug Administration through an advisory board composed of employees of the Administration that shall include—
|
||
|
||
(A) representatives of each of the centers and the science-based offices within the Office of the Commissioner; and
|
||
|
||
(B) experts on trial design, epidemiology, demographics, pharmacovigilance, basic science, and public health; and
|
||
|
||
(6) develop postmarket safety performance measures that are as measurable and rigorous as the ones already developed for premarket review.
|
||
|
||
(June 25, 1938, ch. 675, § 1010, formerly § 910, as added Pub. L. 110–85, title VI, § 602, Sept. 27, 2007, 121 Stat. 898; renumbered § 1010, Pub. L. 111–31, div. A, title I, § 101(b)(2), June 22, 2009, 123 Stat. 1784.)
|